OOIR: Observatory of International Research

Papers

(The median citation count of CNS Drugs is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients	168
Comment on: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”	135
The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Ran	123
Apixaban for the Treatment of Cerebral Venous Sinus Thrombosis: A Single-Centre Experience and Systematic Review of the Literature	100
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio	97
Alternative Routes of Administration of Clozapine	93
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies	76
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?	75
COMT Inhibitors in the Management of Parkinson’s Disease	70
Unmet Needs in Psychodermatology: A Narrative Review	70
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine	67
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis	64
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data	56
Acknowledgement to Referees	54
Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials	53
Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders	51
Managing Chronic Pain: The Ketamine Option	49
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder	49
Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations	45
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine N	44
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants	43
The Effect of Psychotropic Medications on Glaucoma Risk and Intraocular Pressure: A Bayesian Meta-Analysis	39
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review a	38
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	36
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”	36

Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation	35
The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research	34
Narcolepsy: Beyond the Classic Pentad	33
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder	33
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations	33
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis	32
Is the Effect of Intensive Antihypertensive Treatment in Acute Intracerebral Hemorrhage Dependent on Hematoma Volume? A Traditional Meta-analysis of the Effect of Antihypertensive Regimens, a Bayesian	31
A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder	31
Comment on “A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder”'	31
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia	31
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing	31
Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Di	30
Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide	29
Therapeutic Use of γ-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy	29
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study	29
Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Re	28
Targeting Kv7 Potassium Channels for Epilepsy	28
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges	28
Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”	27
Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study	27
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease	26
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of	26
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records	25
Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease	25
Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox–Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials	25
International Trends in Opioid Prescribing by Age and Sex from 2001 to 2019: An Observational Study Using Population-Based Databases from 18 Countries and One Special Administrative Region	24
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis	24
Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics	24
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysi	24
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer’s Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial	23
Correction: Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	23
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational an	22
Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying Therapy	22
Efficacy and Safety of Escitalopram Combined with Tandospirone Citrate in Treating Patients with Vascular Depression and Chronic Insomnia: A Randomized Controlled Trial	22
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults	21
Sodium Oxybate: Practical Considerations and Patient Perspectives	21
Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research	21
Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options	21
Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review	21
Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment for Severe Opioid Use Disorder	20
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study	20
Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	20
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease	20
New and Emerging Drug and Gene Therapies for Friedreich Ataxia	20
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis	19
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial	19
FcRn Inhibitor Therapies in Neurologic Diseases	19
Idiopathic Hypersomnia: Neurobiology, Diagnosis, and Management	19
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders	18
The Effects of Cenobamate and Its Dosage on Cognition: A Retrospective Longitudinal Study in 84 Individuals with Epilepsy	18

Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia	18
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial	18
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy	18
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	18
Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis	18
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study	18
Pharmacological Frontiers: The Rise of Selective NaV1.8 Inhibition for Pain Management	17
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis	17
Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial	17
Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010–2025): 15 Years of Progress (or Lack Thereof)	17
Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial	17
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use	16
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance	16
Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study	16
Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hype	16
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease	16
Predictors of Esketamine Response in Treatment-Resistant Depression: The Role of Temperament and Cumulative Treatment Resistance	16
Acknowledgement to Referees	14
Rett Syndrome: The Emerging Landscape of Treatment Strategies	14
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options	14
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study	14
Pharmacological Management of Borderline Personality Disorder and Common Comorbidities	14
Barriers to Safely Discontinuing Duloxetine: An Urgent Call to Action	14
Pharmacological Management of Apathy in Dementia	14
Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review	13
Targeting Biometals in Alzheimer’s Disease with Metal Chelating Agents Including Coumarin Derivatives	13
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis	13
Effectiveness and Tolerability of Vortioxetine Oral Drops Versus Oral Tablets in Major Depressive Disorder: An Analysis of a Real-World Cohort Study in Switzerland	13
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy	12
Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight	12
Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis	12
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder	12
Understanding the Impact of Stimulants on Sleep in ADHD: Evidence from Systematic Assessment of Sleep in Adults	12
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies	12
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study	12
Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder	12
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors	12
The Utilization of Low Dose Naltrexone for Chronic Pain	12
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development	12
Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studies	12
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studi	12
Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage	12
Impulse Control Disorders in Parkinson’s Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management	12
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis	11
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem	11
The Options for Neuraxial Drug Administration	11
Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”	11
Glutamatergic Modulators for Major Depression from Theory to Clinical Use	11
Author’s Reply to Liu et al.: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”	11
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study	11
Brexpiprazole for the Treatment of Agitation in Older Adults with Alzheimer’s Disease: A Systematic Review, Bayesian Meta-analysis, and Meta-regression	11
Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes	11
Correction: Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review	11
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial	11
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study	11
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis	11
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults	10
Update on Neuroprotection after Traumatic Brain Injury	10
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adult	10
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies	10
Potential Role of Curcumin for the Treatment of Major Depressive Disorder	10
Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care	10
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation	10
Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0–3 Versus 4–5: A Secondary Analysis of the ARAMIS Randomized Trial	10
Motor and Non-motor Complications Following Different Early Therapies in Parkinson’s Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort	10
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial	10
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinic	10
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders	10
Sodium Channel Inhibitors in Clinical Development for Pain Management: A Focused Review	9
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study	9
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research	9
Sex Differences in Outcomes of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Preadmission Use of Antiplatelets	9
Author’s Reply to Zhou et al: Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	9
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period	9
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis	9
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	8
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors	8
The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review	8
Clozapine-Related Tachycardia: An Analysis of Incidence	8
Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis	8

Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?	8
Patterns of Serum Prolactin Elevation Associated with Nine Second-Generation Antipsychotics in a Large Cohort of Patients with Schizophrenia	8
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases	8
Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population	8
Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review	8
A New Dawn in the Management of Narcolepsy	8
Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial	7
Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study	7
Context is a Critical for Psychoactive Drug Effects	7
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia	7
Prioritizing Antihypertensive Agents in Secondary Prevention of Ischemic Stroke: A Retrospective Population-Based Study	7
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial	7
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment	7
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies	7
Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy	7
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape	6
Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Con	6
Psychotropic Drugs Reemerging as Headache Medicines	6
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis	6
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden	6
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review	6
Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022	6
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany	6
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action	6
Current Principles in the Management of Drug-Resistant Epilepsy	6
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets	6
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“	6